LAUSR

Natural killer (NK) cells have a potent cytotoxic activity against leukemia and lymphoma without recognition of human leukocyte antigen (HLA) molecules. Chimeric antigen receptor‐engineered NK cells (CAR‐NK cells) can be produced from the NK92 cell line, peripheral blood, cord blood, and induced pluripotent stem cells for immunotherapy of malignant tumor cells. Recently, the safety and efficacy of HLA‐mismatched allogeneic cord blood‐derived CD19 CAR‐NK cell therapy for CD19‐positive hematological malignancies have been reported. However, the durability of clinical effects has not been clarified. The characteristics of CAR‐NK cells with a strong antileukemia/lymphoma effect and better proliferative capacity without severe adverse effects may be promising for overcoming intractable hematological malignancies as an off‐the‐shelf allogeneic cellular therapy.